Most Viewed Stories
from the last 7 days
Tuesday, February 7, 2012
Radius Health files IPO, aims for $86M
Radius Health Inc., a Cambridge biotech that has raised at least $198 million in financing, on Monday filed to go public in an offering that could raise up to $86.2 million. The filing follows the completed IPO of another Cambridge biotech, Verastem, last month.
Monday, February 13, 2012
Energy Points launches with sustainability metric and $3M
Zik Energy Points Inc. has launched with a new $3 million initial funding round and a way to help companies measure their sustainability efforts - by sophisticated algorithms and a new universal energy usage metric, the EPG.
Thursday, February 9, 2012
Hyatt leaves the Farmville for Spark Capital
Nabeel Hyatt has left the game development world and rejoined the venture capital community, taking a role at Spark Capital as its first venture partner.
Thursday, February 9, 2012
Personal genomes hold eventual promise for treatments
Personal genomes could dramatically improve targeted, personalized treatments for patients with cancer or other illnesses, but it could take another five to 10 years before they pick up traction in the healthcare market, genetics experts told an MIT Enterprise Forum of Cambridge meeting last night.
Monday, February 6, 2012
Stealthy Synchroneuron snaps up $6M in Series A round
Waltham biopharmaceutical Synchroneuron Inc. has raised $6 million in its Series A round of funding, the company said in a release.
Monday, February 13, 2012
Yottaa adds CDN to its website booster offerings
Web performance boosting startup Yottaa Inc. has launched its own content delivery network, or CDN, which the company says will alllow its target audience of small to midsize businesses get the benefits of a CDN like Akamai Inc., but at a much lower cost.
Tuesday, February 7, 2012
Startup Watch: Five you should follow
As part of each week's Startup Report, Mass High Tech highlights five startup companies and their business goals, that are profiled in the New England Tech Directory. Included in this week's Startup Report: Bison Alternatives, GymPact, Lessonsmith, Libboo and Memrise.
Monday, February 6, 2012
InnoCentive buys OmniCompete for innovation challenges
InnoCentive Inc., a Waltham developer of an incentive platform technology, has acquired OmniCompete Ltd., a U.K.-based provider of innovation competitions in the areas of security, energy, healthcare and cloud computing.
Wednesday, February 8, 2012
Akamai CFO Sherman leaves for HubSpot
Akamai chief financial officer J.D. Sherman is leaving the Cambridge Internet data delivery firm after six years, heading across town to venture-backed HubSpot to take a role as president and chief operating officer. James Benson, senior vice president of finance, is taking over as CFO.
Thursday, February 9, 2012
Energy Leaders Breakfast Club:
Energy Leaders Breakfast Club: The future of natural gas
The Energy Leaders Breakfast Club engages in new dialogues by inviting some of the region's thought leaders for breakfast and conversation on issues in the clean energy sector. The following is a transcript of one of these meetings – on the future of natural gas.
Monday, February 6, 2012
Brown University biochip may lead to saliva glucose detector
Brown University researchers have created an experimental biochip that may one day test for miniscule levels of glucose in saliva rather than requiring diabetics to suffer repeated and painful finger pricks, lead scientist Domenico Pacifici told Mass High Tech in an interview.
Monday, February 6, 2012
RainDance, Sony collaborate on sequencing consumables
RainDance Technologies Inc. of Lexington said it has developed methods to manufacture microdroplet-based smart consumables for high-throughput targeted DNA sequencing applications with its partners Digital Biology Co. and Sony DADC Austria AG.
Thursday, February 9, 2012
NanoViricides nabs $5M to take flu fighter to IND
NanoViricides Inc., a Connecticut biotech focused on nanomaterials for antiviral therapy, has closed out a $5 million financing with a $2.5 million tranche from Florida firm Seaside 88 LP.
Thursday, February 9, 2012
SpaceClaim draws up a $4M new funding round
Concord CAD software company SpaceClaim Corp. has raised $4 million in a new fundraising round according to an SEC document. CEO Chris Randles said the funds will help it expand distribution channels to keep up with rapid growth.
Thursday, February 9, 2012
Forsyth gets $750K grant from Gates Foundation
The Forsyth Institute said today that it will get a $750,000 grant to research tuberculosis (TB) biomarkers through the Bill & Melinda Gates Foundation’s Grand Challenges in Global Health program, according to information provided by the institute.
Monday, February 6, 2012
MindChild Medical seeks FDA nod for fetal heart monitor
North Andover startup MindChild Medical Inc. has filed a 510(k) pre-market notification application with the U.S. Food and Drug Administration for its Meridian non-invasive fetal heart monitor.
Thursday, February 9, 2012
iRobot share price falls 33 percent on defense outlook
IRobot Corp.’s stock has lost a third of its value, after the company announced it would likely lose a significant chunk of its revenue from military contracts in the current year, due to constrained Department of Defense budgets.
Wednesday, February 8, 2012
Akamai advances mobile plans with Blaze buy
Akamai Technologies Inc. has bought Canadian company Blaze Software Inc. for an undisclosed amount of cash, to give it a technology that speeds up Web page rendering by optimizing delivery of content.
Wednesday, February 8, 2012
Navidea expands from Ohio into Andover office
Ohio life sciences company Navidea Biopharmaceuticals Inc. is opening a business office in Andover to help it commercialize an imaging agent to detect lymph-node cancer it plans to launch later this year.
Thursday, February 9, 2012
Acetylon wins $15M strategic investment from Celgene
Acetylon Pharmaceuticals Inc. has taken in $15 million in a strategic investment from Celgene Corp., a potential partner or competitor in the treatment of blood cancers.